Viral vectors as vaccine platforms: Deployment in sight

Current Opinion in Immunology

Volumn 23, Issue 3, 2011, Pages 377-382

  Rollier, Christine S ^a   Reyes Sandoval, Arturo ^b   Cottingham, Matthew G ^b   Ewer, Katie ^b   Hill, Adrian V S ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALVAC HIV; BCG VACCINE; CANARYPOX VIRUS VECTOR; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; FOWLPOX VIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMOJEV; JAPANESE ENCEPHALITIS VACCINE; MALARIA VACCINE; RABIES VACCINE; UNCLASSIFIED DRUG; VACCINIA VIRUS VECTOR; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CANARYPOX VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG RESEARCH; DRUG SAFETY; FOWLPOX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; JAPANESE ENCEPHALITIS; MACACA; MALARIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RABIES; SEROTYPE; TUBERCULOSIS; VACCINIA VIRUS; VIRUS IMMUNITY; YELLOW FEVER FLAVIVIRUS;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HUMANS; TREATMENT OUTCOME; VIRAL VACCINES; VIRUS DISEASES;

EID: 79957761310     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.03.006     Document Type: Article

References (40)

1. Liu M.A. Immunologic basis of vaccine vectors. Immunity 2010, 33:504-515.
2. Liu M.A. Gene-based vaccines: recent developments. Curr Opin Mol Ther 2010, 12:86-93.
3. Gao F., Morrison S.G., Robertson D.L., Thornton C.L., Craig S., Karlsson G., Sodroski J., Morgado M., Galvao-Castro B., von Briesen H., et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G, The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 1996, 70:1651-1667.
4. Ada G. Overview of vaccines and vaccination. Mol Biotechnol 2005, 29:255-272.
5. Wei C.J., Boyington J.C., McTamney P.M., Kong W.P., Pearce M.B., Xu L., Andersen H., Rao S., Tumpey T.M., Yang Z.Y., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329:1060-1064.
6. Letourneau S., Im E.J., Mashishi T., Brereton C., Bridgeman A., Yang H., Dorrell L., Dong T., Korber B., McMichael A.J., et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007, 2:e984.
7. Rosario M., Bridgeman A., Quakkelaar E.D., Quigley M.F., Hill B.J., Knudsen M.L., Ammendola V., Ljungberg K., Borthwick N., Im E.J., et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 2010, 40:1973-1984.
8. Santra S., Liao H.X., Zhang R., Muldoon M., Watson S., Fischer W., Theiler J., Szinger J., Balachandran H., Buzby A., et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010, 16:324-328.
9. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., Sun Y.H., La Porte A., Riggs A.M., Lynch D.M., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16:319-323.
10. Brave A., Ljungberg K., Wahren B., Liu M.A. Vaccine delivery methods using viral vectors. Mol Pharm 2007, 4:18-32.
11. Flatz L., Hegazy A.N., Bergthaler A., Verschoor A., Claus C., Fernandez M., Gattinoni L., Johnson S., Kreppel F., Kochanek S., et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 2010, 16:339-345.
12. Reyes-Sandoval A., Berthoud T., Alder N., Siani L., Gilbert S.C., Nicosia A., Colloca S., Cortese R., Hill A.V. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010, 78:145-153.
13. Wilks A.B., Christian E.C., Seaman M.S., Sircar P., Carville A., Gomez C.E., Esteban M., Pantaleo G., Barouch D.H., Letvin N.L., et al. Robust vaccine-elicited cellular immune responses in breast milk following systemic Simian Immunodeficiency Virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J Immunol 2010, 185:7097-7106.
14. Lasaro M.O., Ertl H.C. New insights on adenovirus as vaccine vectors. Mol Ther 2009, 17:1333-1339.
15. Barnett S.W., Burke B., Sun Y., Kan E., Legg H., Lian Y., Bost K., Zhou F., Goodsell A., Zur Megede J., et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010, 84:5975-5985.
16. Kaufman D.R., Bivas-Benita M., Simmons N.L., Miller D., Barouch D.H. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol 2010, 84:5986-5996.
17. Xiang Z., Li Y., Cun A., Yang W., Ellenberg S., Switzer W.M., Kalish M.L., Ertl H.C. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 2006, 12:1596-1599.
18. Dudareva M., Andrews L., Gilbert S.C., Bejon P., Marsh K., Mwacharo J., Kai O., Nicosia A., Hill A.V. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009, 27:3501-3504.
19. Soloff A.C., Liu X., Gao W., Day R.D., Gambotto A., Barratt-Boyes S.M. Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection. Eur J Immunol 2009, 39:2437-2449.
20. Kahl C.A., Bonnell J., Hiriyanna S., Fultz M., Nyberg-Hoffman C., Chen P., King C.R., Gall J.G. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 2010, 28:5691-5702.
21. Gabitzsch E.S., Xu Y., Yoshida L.H., Balint J., Gayle R.B., Amalfitano A., Jones F.R. A preliminary and comparative evaluation of a novel Ad5 [E1- E2b-] recombinant-based vaccine used to induce cell mediated immune responses. Immunol Lett 2009, 122:44-51.
22. Bayer W., Tenbusch M., Lietz R., Johrden L., Schimmer S., Uberla K., Dittmer U., Wildner O. Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. J Virol 2009, 84:1967-1976.
23. Rux J.J., Kuser P.R., Burnett R.M. Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 2003, 77:9553-9566.
24. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., Wilson J.M., Ertl H.C. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002, 76:2667-2675.
25. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., Giles-Davis W., Wilson J.M., Ertl H.C. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003, 170:1416-1422.
26. Reyes-Sandoval A., Fitzgerald J.C., Grant R., Roy S., Xiang Z.Q., Li Y., Gao G.P., Wilson J.M., Ertl H.C. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 2004, 78:7392-7399.
27. Reyes-Sandoval A., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., Gao G., Ertl H.C., Wilson J.C., Hill A.V. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008, 38:732-741.
28. Capone S., Reyes-Sandoval A., Naddeo M., Siani L., Ammendola V., Rollier C.S., Nicosia A., Colloca S., Cortese R., Folgori A., et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010, 29:256-265.
29. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
30. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
31. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
32. Koup R.A., Roederer M., Lamoreaux L., Fischer J., Novik L., Nason M.C., Larkin B.D., Enama M.E., Ledgerwood J.E., Bailer R.T., et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS ONE 2010, 5:e9015.
33. Kibuuka H., Kimutai R., Maboko L., Sawe F., Schunk M.S., Kroidl A., Shaffer D., Eller L.A., Kibaya R., Eller M.A., et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 2010, 201:600-607.
34. Schooley R.T., Spritzler J., Wang H., Lederman M.M., Havlir D., Kuritzkes D.R., Pollard R., Battaglia C., Robertson M., Mehrotra D., et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010, 202:705-716.
35. Killian M.S., Roop J., Ng S., Hecht F.M., Levy J.A. CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy. J Clin Immunol 2009, 29:311-318.
36. Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., Beveridge N.E., Whelan K.T., Hill A.V., McShane H. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS ONE 2007, 2:e1052.
37. Draper S.J., Biswas S., Spencer A.J., Remarque E.J., Capone S., Naddeo M., Dicks M.D., Faber B.W., de Cassan S.C., Folgori A., et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 2010, 185:7583-7595.
38. Kennedy J.S., Greenberg R.N. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009, 8:13-24.
39. Cottingham M.G., Andersen R.F., Spencer A.J., Saurya S., Furze J., Hill A.V., Gilbert S.C. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE 2008, 3:e1638.
40. Alcock R., Cottingham M.G., Rollier C.S., Furze J., De Costa S.D., Hanlon M., Spencer A.J., Honeycutt J.D., Wyllie D.H., Gilbert S.C., et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med 2010, 2:19ra12.